Ongoing Lung Decline With Age Intensified Response
Key claim: A Phase II pilot RCT is testing whether short-course high-dose fisetin improves lung function and reduces cellular-senescence biomarkers in adults aged 60+ with and without a smoking history.
Abstract
This Phase II, randomized, double-blind, placebo-controlled pilot study will evaluate the effects of fisetin, a senolytic flavonoid compound, on lung function and biomarkers of cellular senescence in older adults aged 60 years and older. Participants will include individuals with a history of at least 10 pack-years of smoking as well as age-matched never-smokers. Forty participants will be randomized to receive either fisetin or placebo using a short-course “hit-and-run” dosing strategy (approximately 20 mg/kg/day orally for 2 consecutive days on Days 1-2 and Days 8-9).
Why this matters
Fisetin’s senolytic reputation has rested largely on animal models and small biomarker-focused human pilots; a Phase II RCT explicitly targeting age-related lung decline — and stratifying by smoking history — is one of the first attempts to tie the senolytic rationale to a clinically meaningful organ-function endpoint in older adults. Because it is a trial launch rather than a readout, the finding shifts the fisetin/senolytics record from mechanism and animal data toward a pending human outcome test, and the gap between senolytic enthusiasm and actual human efficacy data remains until results arrive.